{"page_content": "ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT    |  2\nAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage \nbiotechnology company pioneering the development of allogeneic chimeric antigen \nreceptor T cell (AlloCAR T\u2122) products for cancer  . Led by a management team with \nsignificant experience in cell therapy, we are developing a pipeline of \u201coff-the-shelf\u201d \nCAR T cell therapy candidates with the goal of delivering readily available cell \ntherapy on-demand, more reliably, and at greater scale to more patients  .WHO WE ARE\nAt Allogene, our mission is  \nto create and lead the next \nrevolution in cancer treatment \nby delivering to patients the \nfirst AlloCAR T\u2122 products for \nblood cancers and solid \ntumors  . As a team, working \ntogether, we believe we can \nrevolutionize cancer treatment \nby making AlloCAR T\u2122 a reality \nfor patients  .\nThis mosaic is hung in the lobby of our \nheadquarters  . It is made up of photos \nsubmitted by our employees \u2013 photos that \nrepresent their motivations for working at \nAllogene to deliver the first AlloCAR T\u2122 \nproducts to patients  . Through our mosaic  \nand onsite visual media, our team is  \nreminded of the importance of creating a  \ncell therapy that can one day be available  \nto all patients in need  .\n", "metadata": {"source": "NASDAQ_ALLO_2022.pdf", "page": 3, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}